SCHEMBL3540649

SCHEMBL3540649

CCC(C(=O)O)c1[c]cccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
GAA P10253 1/20 0.38
AKR1C3 P42330 4/20 0.36
AKR1C2 P52895 4/20 0.36
ALDH1A1 P00352 2/20 0.36
AKR1C1 Q04828 1/20 0.36
SRC P12931 1/20 0.36
PTGS1 P23219 1/20 0.36
POLB P06746 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA1A P35348 1/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CRHBP P24387 2/20 0.36
CRHR2 Q13324 2/20 0.36
KCNQ2 O43526 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541107 0.86 PPARG (0.38) SRCPOLBADRA1ACYP2C19
SCHEMBL2519498 0.82 CNR2 (0.41) ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3539841 0.81 KMT2A (0.40) LMNAGAAALDH1A1POLBMEN1
SCHEMBL9465771 0.77 LMNA (0.37) LMNAALDH1A1TSHR
SCHEMBL4016238 0.76 PTGS2 (0.46) LMNAHSD17B10AKR1C3AKR1C2ALDH1A1
SCHEMBL9467544 0.75 SRC (0.54) LMNAALDH1A1SRCPTGS1TSHR
SCHEMBL692149 0.74 SRC (0.34) ALDH1A1SRC
SCHEMBL3589887 0.73 LMNA (0.48) LMNATSHR
SCHEMBL533187 0.72 LMNA (0.32) LMNATSHR
SCHEMBL1715 0.72 LMNA (0.59) LMNAHSD17B10GAAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US claimed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US claimed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US claimed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP claimed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO claimed
US-20060049052-A1 Ampholytic buffer having high buffering capacity and high conductivity in isoelectric form THE TEXAS A&M UNIVERSITY SYSTEM (US) 2006-03-09 US claimed
US-8852727-B2 Ink composition, image forming method, and printed matter FUJIFILM CORPORATION (JP) 2014-10-07 US disclosed
EP-2664658-A1 INK COMPOSITION, IMAGE FORMING METHOD, AND PRINT FUJIFILM Corporation (JP) 2013-11-20 EP disclosed
US-20130295344-A1 INK COMPOSITION, IMAGE FORMING METHOD, AND PRINTED MATTER FUJIFILM CORPORATION (JP) 2013-11-07 US disclosed
EP-2492322-A1 Ink composition, image forming method, and printed material Fujifilm Corporation (JP) 2012-08-29 EP disclosed
US-20120213978-A1 INK COMPOSITION, IMAGE FORMING METHOD, AND PRINTED MATERIAL FUJIFILM CORPORATION (JP) 2012-08-23 US disclosed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO disclosed
EP-0780730-B1 Positive-type light-sensitive lithographic printing plate FUJI PHOTO FILM CO LTD (JP) 2002-08-21 EP disclosed
EP-0780730-A2 Positive-type light-sensitive lithographic printing plate FUJI PHOTO FILM CO., LTD. (JP) 1997-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 LMNA 3296/4885HSD17B10 151/4885GAA 171/4885
US-20060049052-A1 Ampholytic buffer having high buffering capacity and high conductivity in isoelectric form ALPP, CA2, CA1 LMNA 1941/4885HSD17B10 2310/4885GAA 80/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 LMNA 3477/4885HSD17B10 166/4885GAA 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.